Business
Illumina completes acquisition of SomaLogic
Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina's multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care.
About this update from Illumina, Inc.
[{"type":"text","content":"Deeply expands leadership in proteomics and multiomics","length":54,"tagName":"p","attribs":{}},{"type":"text","content":"Combined capabilities bring high scalability, flexibility, and affordability into protein analysis ","length":103,"tagName":"p","attribs":{}},{"type":"text","content":"Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries ","length":163,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Jan. 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina's multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care.","length":410,"tagName":"p"},{"type":"image","alt":"Illumina completes acquisition of SomaLogic","displaySize":"","headline":null,"caption":"Illumina completes acquisition of SomaLogic","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/d5637a1ad93df86b597dc8321d0d6ca5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6_HAv9MpvxicpzwuS5e0uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d5637a1ad93df86b597dc8321d0d6ca5","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2873096/Illumina_Inc_completes_acquisition_of_SomaLogic_Photo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Welcoming the SomaLogic team to Illumina is an important milestone in executing the multiomics strategy we outlined in 2024," said Jacob Thaysen, chief executive officer of Illumina. "By combining SomaLogic's highly differentiated proteomics technology with Illumina's industry-leading innovation and global reach, we are strengthening our ability to deliver scalable insights across genomics and proteomics, helping customers unlock more from every sample in support of better outcomes for patients."","length":530,"tagName":"p"},{"type":"text","content":"SomaLogic's technologies provide deep insights into protein function, intera...